Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Phase 1 Completed 63 enrolled Infinity Pharmaceuticals, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objectives of the study are: * Determine the safety and maximum tolerated dose (MTD) of IPI-504 in GIST and STS patients who have failed prior therapies * Recommend a dose for subsequent studies of IPI-504

Timeline

Start: 2005-12
Primary completion: 2010-11
Completion: 2010-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	retaspimycin	Small molecule	—	Intravenous

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Summary

Timeline

Drugs

Indications